12 studies were found.

1.		Recruiting	Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer Condition: Non-Small-Cell Lung Cancer
2.		Recruiting	Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer Conditions: Ovarian Cancer; Peritoneal Neoplasms; Fallopian Tube Neoplasms
3.		No longer recruiting	Phase II Study in Patients with Recurrent Non-Small-Cell Lung Cancer Condition: Non-Small-Cell Lung Cancer
4.		Recruiting	Phase III Study of Cetuximab, Oxaliplatin, 5-FU/LV vs. Oxaliplatin, 5-FU/LV in Patients with Previously Treated Metastatic, EGFR-Positive Colorectal Cancer Condition: Colorectal Cancer
5.		Recruiting	Phase III Study of Irinotecan and Cetuximab vs Irinotecan as Second-Line Treatment in Patients with Metastatic, EGFR-Positive Colorectal Cancer Condition: Colorectal Cancer
6.		Not yet recruiting	A Study in Patients with Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Condition: Ovarian Cancer
7.		No longer recruiting	Study of Cetuximab in Combination with Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer Condition: Carcinoma, Non-Small-Cell Lung
8.		No longer recruiting	A Study of Cetuximab in Patients who have Stage IV Colorectal Cancer Condition: Colorectal Neoplasms
9.		Recruiting	Study of Erbitux (cetuximab) Given Alone to Patients with EGFR-undetectable Metastatic Colon or Rectal Cancer that is Refractory to Chemotherapy Conditions: Colorectal Neoplasms; Metastases; Neoplasm
10.		No longer recruiting	Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma Conditions: Colorectal Neoplasms; Metastases, Neoplasm
11.		Recruiting	Study of gp75 Vaccine in Patients with Stage III and IV Melanoma Condition: Malignant Melanoma
12.		No longer recruiting	Survival in a Randomized Phase III Trial in Patients with Limited Disease (LD) Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG Condition: Carcinoma, Small Cell Lung